Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Accumulated Expenses: 2014-2025

Historic Other Accumulated Expenses for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $21.2 million.

  • Viking Therapeutics' Other Accumulated Expenses fell 14.97% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year decrease of 14.97%. This contributed to the annual value of $17.1 million for FY2024, which is 51.44% up from last year.
  • Latest data reveals that Viking Therapeutics reported Other Accumulated Expenses of $21.2 million as of Q3 2025, which was down 18.45% from $26.0 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Other Accumulated Expenses registered a high of $27.2 million during Q1 2024, and its lowest value of $7.3 million during Q4 2021.
  • In the last 3 years, Viking Therapeutics' Other Accumulated Expenses had a median value of $13.7 million in 2024 and averaged $16.3 million.
  • Per our database at Business Quant, Viking Therapeutics' Other Accumulated Expenses soared by 238.32% in 2024 and then tumbled by 58.22% in 2025.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Other Accumulated Expenses stood at $7.3 million in 2021, then spiked by 79.52% to $13.1 million in 2022, then dropped by 13.84% to $11.3 million in 2023, then soared by 51.44% to $17.1 million in 2024, then dropped by 14.97% to $21.2 million in 2025.
  • Its Other Accumulated Expenses was $21.2 million in Q3 2025, compared to $26.0 million in Q2 2025 and $11.4 million in Q1 2025.